Kezar Life Sciences Balance Sheet Health
Financial Health criteria checks 5/6
Kezar Life Sciences has a total shareholder equity of $134.0M and total debt of $10.3M, which brings its debt-to-equity ratio to 7.7%. Its total assets and total liabilities are $164.1M and $30.0M respectively.
Key information
7.7%
Debt to equity ratio
US$10.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$148.39m |
| Equity | US$134.05m |
| Total liabilities | US$30.04m |
| Total assets | US$164.09m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2KZ0's short term assets ($156.4M) exceed its short term liabilities ($20.4M).
Long Term Liabilities: 2KZ0's short term assets ($156.4M) exceed its long term liabilities ($9.6M).
Debt to Equity History and Analysis
Debt Level: 2KZ0 has more cash than its total debt.
Reducing Debt: 2KZ0's debt to equity ratio has increased from 0% to 7.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2KZ0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2KZ0 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 23.4% each year.